ReviewSmart molecules : open access2026
Targeting the CD47-SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next-generation therapeutic strategies.
Review in Smart molecules : open access, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors have transformed cancer therapy with the programmed cell death protein 1-programmed death-ligand 1 axis, demonstrating substantial efficacy by targeting adaptive immunity across multiple malignancies. However, the limited clinical responses observed in a considerable proportion of patients highlights the need for more effective engagement of innate immune mechanisms. In this context, the cluster of differentiation 47-signal regulatory protein α (CD47-SIRPα) axis has emerged as a next-generation immune checkpoint that regulates phagocytosis. CD47 is a ubiquitously expressed transmembrane glycoprotein containing an N-terminal extracellular immunoglobulin variable-like domain and is frequently overexpressed in both solid tumors and hematological malignancies. By binding to SIRPα on macrophages, CD47 transmits a canonical "don't eat me" signal that suppresses phagocytosis and enables tumor immune evasion. Beyond this canonical role, CD47 interacts with ligands such as thrombospondin-1 and integrins to regulate tumor cell migration, metabolic adaptation, and immune balance within the tumor microenvironment. Importantly, CD47 links innate immune clearance with antigen presentation and downstream adaptive immune activation, positioning it as an actionable node for next-generation therapeutic designs. Although the first-generation CD47 blockade has revealed challenges related to hematologic toxicity, antigen sink effects, and limited monotherapy durability, these challenges have also accelerated the development of more selective, controllable, and context-responsive therapeutic strategies. In this Review, we elucidate the structural features, molecular mechanisms, pathological functions, therapeutic strategies, translational challenges, and emerging solutions of CD47, with the aim of providing a theoretical basis for overcoming current therapeutic limitations and advancing more precise cancer immunomodulatory strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.